Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9 | $11 | $18 | $16 |
| - Cash | $5 | $3 | $2 | $2 |
| + Debt | $10 | $8 | $9 | $9 |
| Enterprise Value | $15 | $17 | $25 | $23 |
| Revenue | $6 | $6 | $6 | $5 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Gross Profit | $4 | $4 | $4 | $3 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| EBITDA | $2 | $2 | $2 | $1 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |
| Net Income | $0 | $1 | $1 | -$0 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| Operating Cash Flow | $0 | $2 | $2 | $0 |
| Capital Expenditures | -$2 | -$1 | -$1 | -$2 |
| Free Cash Flow | -$2 | $0 | $0 | -$1 |